The Value of Circulating Biomarkers in Bicuspid Aortic Valve-Associated Aortopathy
Standard
The Value of Circulating Biomarkers in Bicuspid Aortic Valve-Associated Aortopathy. / Naito, Shiho; Hillebrand, Mathias; Bernhardt, Alexander Martin Justus; Jagodzinski, Annika; Conradi, Lenard; Detter, Christian; Sydow, Karsten; Reichenspurner, Hermann; Kodolitsch, Yskert von; Girdauskas, Evaldas.
in: THORAC CARDIOV SURG, Jahrgang 66, Nr. 4, 06.2018, S. 278-286.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The Value of Circulating Biomarkers in Bicuspid Aortic Valve-Associated Aortopathy
AU - Naito, Shiho
AU - Hillebrand, Mathias
AU - Bernhardt, Alexander Martin Justus
AU - Jagodzinski, Annika
AU - Conradi, Lenard
AU - Detter, Christian
AU - Sydow, Karsten
AU - Reichenspurner, Hermann
AU - Kodolitsch, Yskert von
AU - Girdauskas, Evaldas
N1 - Georg Thieme Verlag KG Stuttgart · New York.
PY - 2018/6
Y1 - 2018/6
N2 - Traditional risk stratification model of bicuspid aortic valve (BAV) aortopathy is based on measurement of maximal cross-sectional aortic diameter, definition of proximal aortic shape, and aortic stiffness/elasticity parameters. However, conventional imaging-based criteria are unable to provide reliable information regarding the risk stratification in BAV aortopathy, especially considering the heterogeneous nature of BAV disease. Given those limitations of conventional imaging, there is a growing clinical interest to use circulating biomarkers in the screening process for thoracic aortic aneurysms as well as in the risk-assessment algorithms. We aimed to systematically review currently available biomarkers, which may be of value to predict the natural evolution of aortopathy in individuals with BAV.
AB - Traditional risk stratification model of bicuspid aortic valve (BAV) aortopathy is based on measurement of maximal cross-sectional aortic diameter, definition of proximal aortic shape, and aortic stiffness/elasticity parameters. However, conventional imaging-based criteria are unable to provide reliable information regarding the risk stratification in BAV aortopathy, especially considering the heterogeneous nature of BAV disease. Given those limitations of conventional imaging, there is a growing clinical interest to use circulating biomarkers in the screening process for thoracic aortic aneurysms as well as in the risk-assessment algorithms. We aimed to systematically review currently available biomarkers, which may be of value to predict the natural evolution of aortopathy in individuals with BAV.
KW - Aorta/diagnostic imaging
KW - Aortic Aneurysm/blood
KW - Aortic Valve/abnormalities
KW - Bicuspid Aortic Valve Disease
KW - Biomarkers/blood
KW - Blood Vessel Prosthesis Implantation
KW - Clinical Decision-Making
KW - Dilatation, Pathologic
KW - Heart Valve Diseases/complications
KW - Heart Valve Prosthesis Implantation
KW - Humans
KW - Predictive Value of Tests
KW - Prognosis
KW - Risk Factors
U2 - 10.1055/s-0036-1583525
DO - 10.1055/s-0036-1583525
M3 - SCORING: Review article
C2 - 27148933
VL - 66
SP - 278
EP - 286
JO - THORAC CARDIOV SURG
JF - THORAC CARDIOV SURG
SN - 0171-6425
IS - 4
ER -